In this issue:
Effect of exercise on CVD risk in early-stage breast cancer
SC vs IV trastuzumab for HER2+ early breast cancer
Neratinib + capecitabine in HER2+ brain metastases
QoL with extended continuous vs intermittent letrozole
Risk and impact of complications in immediate breast reconstruction
Olaparib: OlympiAD final analysis & tolerability profile
ExteNET HRQoL data for neratinib
Durvalumab + standard NACT in early TNBC
Recommendation against CTx in cognitively impaired older patients
A psychosexual intervention benefits breast cancer survivors
Please login below to download this issue (PDF)